Ten-day Decitabine with Venetoclax in Acute Myeloid Leukemia: A Single-arm Phase 2 Trial

BACKGROUND: Venetoclax with hypomethylating agents is a new standard of care for newly diagnosed (ND) patients with acute myeloid leukemia (AML) who are 75 years or older, or unfit for intensive chemotherapy. Pharmacodynamic studies have suggested superiority of the longer 10-day regimen of decitabi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Lancet Haematol
Main Authors: DiNardo, Courtney D., Maiti, Abhishek, Rausch, Caitlin R., Pemmaraju, Naveen, Naqvi, Kiran, Daver, Naval G., Kadia, Tapan M., Borthakur, Gautam, Ohanian, Maro, Alvarado, Yesid, Issa, Ghayas C., Montalban-Bravo, Guillermo, Short, Nicholas J., Yilmaz, Musa, Bose, Prithviraj, Jabbour, Elias J., Takahashi, Koichi, Burger, Jan, Garcia-Manero, Guillermo, Jain, Nitin, Kornblau, Steven M., Thompson, Philip A., Estrov, Zeev, Masarova, Lucia, Sasaki, Koji, Verstovsek, Srdan, Ferrajoli, Alessandra, Weirda, William G., Wang, Sa A., Konopleva, Sergej, Chen, Zhining, Pierce, Sherry A., Ning, Jing, Qia, Wei, Ravandi, Farhad, Andreeff, Michael, Welch, John S., Kantarjian, Hagop M., Konopleva, Marina Y.
Formato: Artigo
Idioma:Inglês
Publicado em: 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7549397/
https://ncbi.nlm.nih.gov/pubmed/32896301
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S2352-3026(20)30210-6
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados